As with everything else in 2020, clinical trials and human factors studies look a little different this year. The pandemic has posed a challenge in conducting studies that would ordinarily require face-to-face interaction. During the upcoming webinar, “Clinical Trials & Human Factors Studies During a Pandemic”, experts will discuss not only the challenges encountered when conducting these studies but also the considerations and strategies as a result, and some lessons learned and long-term opportunities to help stakeholders streamline and enhance their procedures in the post-pandemic era. This webinar, which will occur from 12:00–1:30 pm ET on Monday, December 7, is highly recommended for professionals in clinical, human factors, instructional learning, quality and regulatory.
Featured speakers include:
- Deb Billings, Ph.D. and Sophia Kalita, senior human factors consultants, Agilis Consulting
- Marc Bonaca, M.D., executive director, CPC Clinical Research, & Professor of Medicine, Cardiology, & Vascular Medicine, director of vascular research, University of Colorado
- Nicole Jaeger, associate director, research & community health operations, CPC Clinical Research
Join MedTech Intelligence for “Clinical Trials & Human Factors Studies During a Pandemic”, December 7, 2020, 12–1:30 pm ET.
Related Articles
-
AI not only improves data collection and analysis, it impacts which products are engaged in clinical trials, determines necessary medical criteria, helps design the trials and can even choose the best participating facilities. The result is, organizations that leverage AI…
-
“Content of Human Factors Information in Device Marketing Submissions” and “Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers” are now open for comment.
-
Hägen, who was a contributor to Medtech Intelligence, spent 28 years building BlackHägen Design to support clients in the development of “mission-critical” products. He was pivotal in the advocacy of human factors and good design practices for medical devices and…
-
The draft guidance covers DCT design, informed consent, the use of remote clinical trial visits, safety monitoring and software used in conducting DCTs for drugs, biological products, and devices. The comment period is open until August 1, 2023.
